US devices industry will seek to fine-tune CMS' 2008 inpatient schedule
This article was originally published in Clinica
US medical device companies have given a guarded welcome to the 2008 inpatient schedule, which promises an average 3.5% rise in payments to hospitals next year.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.